Susan Thornton, CEO of Cutaneous Lymphoma Foundation and CRISPR Therapeutics's Dr. Mary-Lee Dequeant recently discussed CAR T therapy in a CLF #IndustrySpotlight . Check out the video here: bit.ly/3CJomrw. You can also learn more about Cutaneous Lymphoma here: bit.ly/3Rw2m7w

We are honored to continue our support of Rosie's Place, a local #Boston nonprofit. Our #CRISPRTX employees created more than 400 care packages with various resources for women in need. Together we are committed to giving back to our community!

Today, CRISPR Therapeutics’ Diversity, Equity and Inclusion (DE&I) committee welcomed Rear Admiral Richardae Araojo from the FDA Office of Minority Health and Health Equity to learn about advancing racial and ethnic minority participation in clinical trials.

The CRISPR Therapeutics Patient Advocacy team is attending the American Cancer Society Research and Health Equity Breakfast to align on ways to accelerate research and to help advance health equity across the country. Learn more here: bit.ly/3e16Chb #fightcancer

Community voices add value to our research and help advance our mission towards developing potentially transformative gene-based medicines. With patients alongside us, our goal is to move forward together. Find our inspiration here: bit.ly/3ChsSMl

CRISPR Therapeutics attended the 4th annual #KCRS22 hosted by KidneyCAN. This event fostered discussions for innovation and highlighted advances in treatment development. Learn more here: bit.ly/3Qg7hcl

With innovation at our core, here’s a fly-through tour of our new U.S. R&D HQ in #Boston . The facility brings together our team of passionate, energetic employees to pioneer development of transformative gene-based medicines. Learn more about #CRISPRTX crisprtx.com/careers

Today, we announced the acceptance of two presentations at the upcoming Society for Immunotherapy of Cancer Annual Meeting. Learn more here: bit.ly/3SWgwjn   #SITC22

In recognition of #sicklecellawarenss month, we are spotlighting facts about the impact #SCD can have on the body. For more information, learn more about this condition on the Sickle Cell Disease Association website: bit.ly/3S0rNz7

The CRISPR Therapeutics team encourages you to show your support and #LightitRed or #TurnitRed in honor of September being #leukemia and #lymphoma awareness month.

We are pleased to announce that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130™ for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS). Read more here: bit.ly/3dPJmmI

Today we announced that the FDA granted exa-cel a rolling review for the potential treatment of sickle cell disease and transfusion-dependent beta thalassemia. Read more here: bit.ly/3Rhpk2d

September is #BloodCancerAwarenessMonth . Blood cancers, such as #leukemia and #lymphoma , affect the production and function of blood cells in the body. These conditions can affect both children and adults.

We celebrated the official opening of our CRISPR Therapeutics R&D HQ in #Boston ! We're excited for the impactful work we will accomplish in this space as we continue to focus on innovation that matters. Thank you Breakthrough Properties & Tishman Speyer for the collaboration on this facility.

Today, we announced our second quarter earnings results. Read more about our recent highlights and outlook: bit.ly/3df1YMk